Study guide
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease
Key Takeaways Explain This Topic AI
ACOG's 2024 update suggests forgoing routine Rh testing and RhD immune globulin for abortion or pregnancy loss before 12 0/7 weeks; where local protocol still directs it, the dose is 50 mcg before 12 weeks and 300 mcg at 12 weeks or later.
Medical management of early pregnancy loss with mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg exceeds 90 percent success, outperforming misoprostol alone.
A complete hydatidiform mole is androgenetic 46,XX with no fetal tissue, a snowstorm ultrasound pattern, and hCG often above 100,000 mIU/mL, while a partial mole is triploid with fetal tissue and near-normal hCG.
After molar evacuation, hCG is followed weekly until negative on three consecutive tests and then monthly for 6 months, with reliable contraception required throughout surveillance.
Septic abortion is a surgical emergency requiring broad-spectrum intravenous antibiotics plus immediate uterine evacuation, not antibiotics alone.
Last updated: September 2026
Obstetric complications during the antepartum period require prompt clinical recognition, accurate differential diagnosis, and decisive action. Whether addressing early pregnancy bleeding, life-threatening third-trimester hemorrhage, alterations in amniotic fluid volume, or the onset of preterm labor, the Certified Nurse-Midwife operates as both primary clinician and collaborative partner within the perinatal care team.
First-Trimester Vaginal Bleeding & Early Pregnancy Loss
Vaginal bleeding occurs in approximately 20% to 25% of all pregnancies during the first trimester. The primary clinical differential diagnosis includes spontaneous abortion, ectopic pregnancy, gestational trophoblastic disease, and benign cervical/vaginal pathology (e.g., cervical polyp, ectropion, infection).
Spontaneous Abortion Categories & Clinical Findings
Early pregnancy loss is defined as a nonviable, intrauterine pregnancy with either an empty gestational sac or an embryo/fetus without cardiac activity prior to 12 6/7 weeks gestation.
Classification Cervical Internal Os Vaginal Bleeding & Cramping Ultrasound Findings Clinical Management
Threatened Abortion Closed Mild to moderate vaginal bleeding; mild or no pelvic cramping Viable intrauterine embryo with documented fetal cardiac activity Expectant management; reassurance; pelvic rest; administer RhIG if Rh-negative; avoid bed rest (no proven benefit)
Inevitable Abortion Open Moderate to heavy vaginal bleeding; progressive cramping Gestational sac low in uterus or cervical canal; cardiac activity may or may not be present Expectant, medical (mifepristone + misoprostol), or surgical uterine evacuation; pain control
Incomplete Abortion Open Heavy bleeding with passage of tissue; severe cramping Retained products of conception (thickened, irregular endometrial tissue >15 mm); gestational sac collapsed Medical evacuation or surgical aspiration (MVA/EVA); monitor for hemodynamic instability and hemorrhage
Complete Abortion Closed (or closing) History of heavy bleeding and tissue passage; symptoms now subsiding Empty endometrial cavity; stripe thickness typically <15 mm; no retained tissue Expectant; confirm serial falling hCG to zero; emotional support; contraception counseling
Missed Abortion Closed Minimal or no bleeding; cessation of pregnancy symptoms Nonviable intrauterine pregnancy (embryo ≥7 mm without cardiac activity or sac mean diameter ≥25 mm without embryo) Expectant, medical, or surgical management; discuss patient preference and timeframe
Septic Abortion Typically open with purulent discharge Bleeding variable; severe cramping; uterine tenderness; fever (>38.0°C), foul odor, leukocytosis Retained products of conception; intraabdominal free fluid; gas in uterine cavity Medical emergency: broad-spectrum IV antibiotics (e.g., ampicillin + gentamicin + clindamycin) and immediate surgical curettage
Treatment Modalities for Early Pregnancy Loss
For stable patients without infection or heavy hemorrhage, three management strategies exist:
Expectant Management: Safe for up to 2 to 4 weeks in stable patients with threatened, incomplete, or missed abortion. Complete expulsion occurs in 70% to 80% within this window, though unpredictable timing and bleeding are disadvantages.
Medical Management: Combining a progesterone receptor antagonist with a prostaglandin analogue yields superior efficacy (>90% success) compared to prostaglandin alone:
Mifepristone: 200 mg PO single dose, followed 24 hours later by:
Misoprostol: 800 mcg buccally or vaginally (repeated once at 48 hours if expulsion is incomplete).
Side effects: Cramping, heavy bleeding, nausea, vomiting, diarrhea, and low-grade pyrexia.
Surgical Management: Manual vacuum aspiration (MVA) under local paracervical anesthesia or electric vacuum aspiration (EVA) in the operating room. Indicated for severe hemorrhage, hemodynamic instability, intrauterine infection, suspected molar gestation, or patient preference.
Rh Alloimmunization Prophylaxis: All unsensitized Rh-negative individuals with first-trimester bleeding or loss must receive Rh immune globulin (RhIG) within 72 hours of bleeding onset: 50 mcg IM for gestational age <12 0/7 weeks; 300 mcg IM for gestational age ≥12 0/7 weeks.
Gestational Trophoblastic Disease (Hydatidiform Mole)
Gestational trophoblastic disease encompasses a spectrum of cellular proliferations arising from placental villous trophoblast.
Complete Hydatidiform Mole: Results from the fertilization of an enucleated ovum by a single sperm that duplicates its DNA ( 46,XX , androgenetic) or by two sperm (46,XY). Characterized by total absence of embryonic/fetal tissue, diffuse trophoblastic hyperplasia, generalized hydropic villi, and markedly elevated beta-hCG levels (often >100,000 mIU/mL). Classic ultrasound displays a "snowstorm" or "bunch of grapes" intrauterine pattern. Clinical features include hyperemesis gravidarum, early-onset preeclampsia (<20 weeks), theca lutein ovarian cysts, and clinical hyperthyroidism.
Partial Hydatidiform Mole: Results from fertilization of a normal ovum by two sperm, yielding a triploid karyotype (69,XXX, 69,XXY, or 69,XYY) . Contains fetal tissue alongside localized hydropic villi. Beta-hCG levels are typically mildly elevated or normal, and presentation mimics an incomplete or missed abortion.
Management: Suction curettage evacuation under ultrasound guidance. Baseline chest radiograph is obtained to rule out pulmonary trophoblastic embolization. Serial quantitative beta-hCG levels are tracked weekly until negative for three consecutive weeks, then monthly for 6 months to monitor for persistent gestational trophoblastic neoplasia (choriocarcinoma). Reliable contraception is strictly mandated throughout surveillance.
Note
2024 update on RhD immune globulin before 12 weeks. ACOG's Clinical Practice Update (2024) and a concurrent SMFM statement now suggest forgoing routine Rh testing and RhD immune globulin for abortion or pregnancy loss at less than 12 0/7 weeks , because the likelihood of alloimmunization at that gestational age is very low and the prior recommendation rested on very low-quality evidence. The 50 mcg mini-dose described above remains the correct dose wherever local or state protocol still directs administration, and the 300 mcg dose remains standard at 12 0/7 weeks and beyond. Know which protocol governs your practice, and be able to explain the change to a patient who has heard the older rule.